China Resources Pharma to Divest 17.87% Stake in Tianmai Bio for $205 Million
China Resources Pharmaceutical Group Co., Ltd. (HKG: 3320) announced plans to sell a 17.87% stake in...
China Resources Biopharmaceutical
China Resources Biopharmaceutical Partners with Hefei Institute and Afana Bio for Joint Lab
China Resources Biopharmaceutical Co., Ltd has announced a strategic partnership with the Hefei Comprehensive National...
ImmVira’s MVR-C5252 Receives NMPA Approval for Glioma Treatment Development
China-based biotechnology company ImmVira has received approval from the National Medical Products Administration (NMPA) for...
China Resources Biopharmaceutical Secures RMB 600 Million in Series B Funding
China Resources Biopharmaceutical Co., Ltd has announced the completion of a Series B financing round,...
Nankai University Establishes Postgraduate Practice Base with China Resources Biopharma
The College of Pharmacy at Nankai University has established a postgraduate practice base at the...
China Resources Partners with Fosun Pharma to Expand Global Healthcare Footprint
China Resources (Holdings) Co. Ltd (HKG: 3320) has entered into a strategic partnership with compatriot...
ImmVira Partners with China Resources Biopharmaceutical on Oncolytic Virus MVR-C5252 for Gliomas
China-based biotech company ImmVira has entered into an exclusive partnership with compatriot firm China Resources...